Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov;11(6):540-552.
doi: 10.1111/cts.12567. Epub 2018 Aug 7.

Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development

Meric Ovacik  1 , Kedan Lin  2
Affiliations

Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development

Meric Ovacik et al. Clin Transl Sci. 2018 Nov.

Abstract

The tutorial introduces the readers to the fundamentals of antibody pharmacokinetics (PK) in the context of drug development. Topics covered include an overview of antibody development, PK characteristics, and the application of antibody PK/pharmacodynamics (PD) in research and development decision-making. We also discuss the general considerations for planning a nonclinical PK program and describe the types of PK studies that should be performed during early development of monoclonal antibodies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic structure of IgG antibody: A simplified representation of IgG structure. VL = variable light chain; VH = variable heavy chain; CH1 = constant heavy chain domain 1; CH2 = constant heavy chain domain 2; CH3 = constant heavy chain domain 3; CDR = complementary determining region (responsible for specific antigen binding); Fab = fragment antigen‐binding (Fab); Fc = fragment crystallizable region; Fv = fragment variable.
Figure 2
Figure 2
Representative PK profiles for linear and nonlinear clearance at the same doses. (a) The linear PK profiles with parallel elimination slopes. (b) The nonlinear PK profiles: the slope of the terminal phase decreases as the dose increases and approaches linear PK range as the dose reaches saturation dose level.
Figure 3
Figure 3
The alignment of major PK/PD‐related studies with the decision points of mAb development in both objectives and recommended studies.
See this image and copyright information in PMC

References

    1. Reichert, J.M. Antibodies to watch in 2017. MAbs. 9, 167–181 (2017). - PMC - PubMed
    1. Weiner, G.J. Building better monoclonal antibody‐based therapeutics. Nat. Rev. Cancer. 15, 361–370 (2015). - PMC - PubMed
    1. FDA . Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations 2016 [Available from: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelope....
    1. Cruse, J.M. & Lewis, R. Atlas of Immunology, Third Edition, (CRC Press Taylor & Francis Group; 2010).
    1. Kohler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 256, 495–497 (1975). - PubMed

Publication types

Substances